betamethasone | 2990-65-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: betamethasone
• 英文别名: 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione；(8S,9R,10S,13S,14S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
• CAS: 2990-65-0
• 化学式: C₂₂H₂₉FO₅
• 分子量: 392.468
• InChiKey: UREBDLICKHMUKA-IVVBZYGOSA-N

物化性质

• 沸点：
  568.2±50.0 °C(Predicted)
• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  28
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  94.8
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• [EN] LIPID PRODRUGS OF NEUROSTEROIDS<br/>[FR] PROMÉDICAMENTS LIPIDIQUES DE NEUROSTÉROÏDES
  申请人：PURETECH LYT INC

  公开号：WO2021159021A1

  公开（公告）日：2021-08-12

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统导向的脂质前药、其药物组合物、制备此类前药和组合物的方法，以及提高包含在脂质前药中的治疗剂的生物利用度或其他特性的方法。本发明还提供了治疗如本文所述的疾病、紊乱或状况的方法，包括向有需要的患者施用所述的脂质前药或其药物组合物。
• FATTY ACID DERIVATIVES
  申请人：——

  公开号：US20010006962A1

  公开（公告）日：2001-07-05

  The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and carboxylic acid ester groups are modified by replacing one or more of these functional groups by a lipophilic group selected from those of the formula: RCOO—, RCONH—, RCOS—, RCH 2 O—, RCH 2 NH—, —COOCH 2 R, —CONHCH 2 R and —SCH 2 R, wherein R is a lipophilic moiety selected from cis-8-heptadecenyl, trans-8-heptadecenyl, cis-10-nonadecenyl and trans-10-nonadecenyl.

  生物活性化合物（例如药物和农药）的性质，其中分子结构中包含来自醇、醚、苯基、氨基、酰胺、硫醇、羧酸和羧酸酯基团中的一个或多个官能团，通过用来自以下公式的亲脂基团替换其中一个或多个这些官能团来进行修改：RCOO—、RCONH—、RCOS—、RCH2O—、RCH2NH—、—COOCH2R、—CONHCH2R和—SCH2R，其中R是从顺式-8-十七碳烯基、反式-8-十七碳烯基、顺式-10-十九碳烯基和反式-10-十九碳烯基中选择的亲脂基团。
• NOVEL 11 BETA-HYDROXYANDROSTA-4-ENE-3-ONES
  申请人：Patel Jiten Ranchhodbhai

  公开号：US20090054388A1

  公开（公告）日：2009-02-26

  The invention provides 11β-hydroxyandrosta-4-ene-3-one compounds of Formula I, or physiologically acceptable salts or solvates thereof: wherein R 4 represents a moiety selected from a group consisting of (A), (B) and (C), with a proviso that when R 4 represents moiety (C), Z is S:

  该发明提供了Formula I的11β-羟基雄烯酮化合物，或其在生理上可接受的盐或溶剂中的衍生物：其中R4代表从(A)、(B)和(C)组成的一组中选择的一个基团，但要注意当R4代表基团(C)时，Z为S:
• Blood cell deficiency treatment method
  申请人：——

  公开号：US20030083231A1

  公开（公告）日：2003-05-01

  The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3&bgr;-yl)-&bgr;-D-glucopyranosiduronate, 16&agr;,3&agr;-dihydroxy-5&agr;-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

  该发明涉及使用化合物治疗多种疾病，如血小板减少症、中性粒细胞减少症或放疗延迟效应。可以用于该发明的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-3β-基)-β-D-葡糖吡喃糖醛酸酯、16α,3α-二羟基-5α-雄甾酮-17-酮或3,7,16,17-四羟基雄烷-5-烯、3,7,16,17-四羟基雄烷-4-烯、3,7,16,17-四羟基雄烷-1-烯或3,7,16,17-四羟基雄烷可用于治疗方法中。
• Modulators of the glucocorticoid receptor
  申请人：Pfizer Inc.

  公开号：US20040138262A1

  公开（公告）日：2004-07-15

  The present invention provides compounds of the formula 1 wherein A is of the formula 2 and X, Y, n, R 1 -R 25 are as described in the specification which are modulators of the glucocorticoid receptor and are thus useful for the treatment of animals requiring glucocorticoid receptor agonist therapy. Glucocorticoid receptor modulators are useful in the treatment of certain inflammatory conditions.

  本发明提供了一些化合物，其化学式为1，其中A的化学式为2，X、Y、n、R1-R25如说明书所述，这些化合物是糖皮质激素受体调节剂，因此对需要糖皮质激素受体激动剂治疗的动物有用。糖皮质激素受体调节剂在治疗某些炎症病症方面是有用的。